[Efficacy and safety of Polatuzumab Vedotin in combination with rituximab plus bendamustine in patients with relapsed/refractory diffuse large B-cell lymphoma: a single center analysis]

Zhonghua Xue Ye Xue Za Zhi. 2022 Jan 14;43(1):66-69. doi: 10.3760/cma.j.issn.0253-2727.2022.01.013.

[Article in Chinese]

Authors

F C Kong¹, M Yu¹, Y L Zhou¹, S X Wang¹, F Li¹

Affiliation

¹ Center of Hematology, Institute of Lymphoma of Nanchang University, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.

PMID: 35231996
PMCID: PMC8980657
DOI: 10.3760/cma.j.issn.0253-2727.2022.01.013

No abstract available

MeSH terms

Antibodies, Monoclonal
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Bendamustine Hydrochloride / therapeutic use
Humans
Immunoconjugates* / adverse effects
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Rituximab / adverse effects

Substances

Antibodies, Monoclonal
Immunoconjugates
Rituximab
Bendamustine Hydrochloride
polatuzumab vedotin

Grants and funding

基金项目：国家自然科学基金（81960043、81600180）；江西省自然科学基金（20192ACB20030、20203BBGL73197）